CORPORATE PRESENTATION SEPTEMBER 2021 - Mziq

Page created by Pamela Casey
 
CONTINUE READING
CORPORATE PRESENTATION SEPTEMBER 2021 - Mziq
CORPORATE
  PRESENTATION
SEPTEMBER 2021
CORPORATE PRESENTATION SEPTEMBER 2021 - Mziq
DISCLAIMER
IMPORTANT NOTICE.

This presentation (“Presentation”) is an overview of Lobe Sciences Ltd. (the “Company”) and is for information purposes only and should not be relied on for the purposes of making an investment decision. This Presentation does not, and it is not intended to, provide any
financial, legal, accounting, or tax advice, and must not be relied upon by you in that regard. The Presentation should not be used, or relied upon by you, as a substitute for your independent research or consultation with your own financial, legal or tax advisors. There are
significant risks associated with an investment in the Company.

The information contained in this Presentation has been provided by the Company or obtained from publicly available sources or third-party sources and has not been independently verified. While the Company has not verified third party information, nevertheless, it
believes that it obtained the information from reliable sources and has no reason to believe it is not accurate in all material respects. No representation or warranty express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or
correctness of the information or any opinions contained herein and nothing in this Presentation is, or shall be relied upon as, a promise or representation by the Company. It is not the intention to provide, and you may not rely on these materials as providing, a complete or
comprehensive analysis of the Company’s financial or trading position or prospects. The information and any opinions presented herein are provided as at the date of this document based on general information gathered at the time of writing and are subject to change
without notice. None of the Company nor any of its affiliates, directors, officers, employees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of these materials or its contents or otherwise
arising in connection with this Presentation. This Presentation and any related oral presentations do not constitute an offer or invitation to subscribe for, purchase or otherwise acquire any securities or other debt instruments of the Company and nothing contained herein or
its Presentation shall form the basis of any contract or commitment whatsoever, nor does it constitute a recommendation regarding the securities of the Company.

All dollar amounts stated in this Presentation are expressed in United States currency, except where otherwise indicated.

FORWARD-LOOKING INFORMATION & FORWARD-LOOKING STATEMENTS CAUTIONARY STATEMENT
Certain statements in this Presentation may constitute forward-looking information, including future-oriented financial information and financial outlooks, within the meaning of applicable securities laws. This Presentation contains forward-looking information relating to
the Company’s future outlook and anticipated events or results and may include statements regarding its financial results, future capital expenditures, cash flow, investment payouts, valuations, plans, objectives, potential synergies, industry trends, growth opportunities and
other matters (“forward-looking statements”). These statements relate to future events or future performance. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “budget”, “plan”, “estimate”, “expect”, “forecast”,
“may”, “might” “will”, “project”, “potential”, “target”, “intend”, “could”, “might”, “should”, “believe” , “likely”, and similar expressions or variations (including negative variations) of such words or phrases.

Forward-looking statements are based on the opinions, assumptions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from
those anticipated in the forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. These statements are not
guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information or forward-looking statements. These risks,
uncertainties and other factors include, but are not limited to risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and
external sources, and/or inability to access sufficient capital on favorable terms; the ability of the Company to implement its business a acquisition strategies, and the other risks common for a business such as the Company’s. The foregoing factors are not intended to be
exhaustive. Although the company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ
from those. The Company cannot guarantee future results, level of activity, performance or achievements and there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking statements. The forward-
looking statements contained in this Presentation are expressly qualified by this cautionary statement. The Company undertakes no obligation to update or revise publicly any forward-looking statements except as required by applicable securities legislation.

The forward-looking statements made herein relate only to events or information as of the date on which the statements are made. The reader is cautioned not to place undue reliance on forward-looking statements.

This presentation contains information regarding the past performance of a company, including but not limited to the financial information of this Presentation. Recipients of this Presentation should be aware that that past performance should not be relied upon as being
indicative of future performance.

Lobe Sciences Ltd. is publicly traded on the Canadian Stock Exchange under the ticker LOBE and more information on Lobe Sciences can be found on the CSE website at https://thecse.com/en/listings/life-sciences/lobe-sciences-ltd

Not for public distribution and not for release or distribution outside Canada
Importantly, the distribution of this Presentation in other jurisdictions outside Canada may also be restricted by law and any such restrictions should be observed. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.
CORPORATE PRESENTATION SEPTEMBER 2021 - Mziq
WHO WE ARE
Lobe Sciences is a life sciences company focused on                         Vision:
psychedelic medicines. The Company is engaged in drug         Developing and delivering solutions to
research and development using psychedelic compounds             improve the human condition.
and the development of innovative devices and delivery
mechanisms to improve mental health and wellness.

The Company plans to develop transformational
medicines and devices as we build a growing portfolio of                      Mission:
intellectual property to support wellness and improve         To identify and develop transformative
mental health.                                              new medicines, compounds and devices to
                                                            improve health and provide new pathways
We focus on clinical development of devices and medicines                  to medicines.
to treat specific medical conditions and brain traumas.
Additionally, generating ongoing cash flow from licensing
and other agreements.
CORPORATE PRESENTATION SEPTEMBER 2021 - Mziq
INTRODUCTION TO PSYCHEDELICS

                         Psilocybin            DMT             LSD             MDMA

                    Psychedelic drugs exert psychoactive effects on users:
                          - Psilocybin
                          - Dimethyltryptamine (DMT)
                          - Lysergic acid diethylamide (LSD)
                          - Methylenedioxymethamphetamine (MDMA)

                    Serotonin regulates mood, happiness, and anxiety.

Photos by ACS.org   Psychedelics activate serotonin receptors in the brain—5HT2A.
CORPORATE PRESENTATION SEPTEMBER 2021 - Mziq
HISTORY OF PSYCHEDELICS                                                                                                   PSILOCYBIN REFORM IN THE USA
                            ~5000 BCE
        Frescos of mushroom-                                      ~ 4000 BCE
       holding shamans were                                       In a cave near the town of                                                 May 2019
      depicted in caves on the                                    Villar del Humo in Spain,                                     Denver, CO becomes the
              Tassili plateau of                                                                                                                              June 2019
                                                                  the Selva Pascuala mural                                      first city to decriminalize
         Southeastern Algeria.                                                                                                                   psilocybin   Oakland, CA follows
                                                                  depicts what appear to be
                                                                                                                                                              suite and decriminalizes
                                                                  psilocybin mushrooms.
                           ~1500 BCE                                                                                                   January 2020           psilocybin
                                                                  These paintings provide
                 Archaeological
                                                                  the earliest evidence of                                                Santa Cruz, CA
           “mushroom stones”
                                                                  the use of psychedelic                                                  decriminalizes      September 2020
                 indicate that a
                                                                  mushrooms in Europe.                                                        psilocybin
      sophisticated mushroom                                                                                                                                  Ann Arbor, MI
     cult existed in Guatemala.                                   1000 BCE                                                                                    decriminalizes psilocybin
                                                                  Statues in Mexico depicted                                        November 2020
                   1799: October
                                                                  Psilocybe mexicana with god-
            In London, the first                                  like figures emerging from it,                                       Oregon to become
        psychedelic mushroom                                      indicating religious use.                                              the first state to   June 2021
                experience was                                                                                                           allow the use of
                                                                                                                                                              California Senate
     documented in a scholarly                                    1904: August                                                               psilocybin in
                                                                                                                                                              Passage of
         journal by Dr. Everard                                                                                                        therapy and votes
                                                                   American mycologist Franklin                                                               Groundbreaking
                                                                                                                                         to decriminalize
      Brande. The mushrooms                                        Sumner Earle was the first                                                                 Psychedelic Reform Bill
                                                                                                                                                psilocybin
        were determined to be                                      person to collect and identify
       Psilocybe semilanceata.                                     Psilocybe cubensis in Cuba.
1.    https://psychedelictimes.com/psychedelic-timeline/?fbclid=IwAR1Abz3BgbYlyd_29411QT11Vom7EgSO5IG9WSxXQU_xKJGMifeXM0h8C-Q
2.    https://psychedelicinvest.com/mapping-psilocybin-reform/
CORPORATE PRESENTATION SEPTEMBER 2021 - Mziq
NEAR TERM FOCUS
            Treatments for mTBI and PTSD with NAC and Psychedelics
                                           Current preclinical study ongoing with
                                           University of Miami for the treatment of
                                           PTSD and/or traumatic brain injury with
                                           PTSD

Delivery Devices for Efficient Drug Delivery
   Engineering design and development for Nasal
   Mist Delivery Device has begun
CORPORATE PRESENTATION SEPTEMBER 2021 - Mziq
THE MARKET OPPORTUNITY - PTSD
            10%                                           8M                                     $16T                                      20%                                             7%                                        40%
        Approximately the                          Number of adults        Estimated global                                          Percentage of combat                            Percentage of                              Approximately the
      percentage of people                     suffering from PTSD each expenditure on mental                                       veterans suffering from                       adolescents between                          percentage of people
       suffering from PTSD                                year.         health by 2030 (in USD).                                            PTSD.                                ages of 17-18 suffering                      impacted by mTBI that
      during their lifetime.                                                                                                                                                           from PTSD.                                suffer from PTSD.

                                                                    THE MARKET OPPORTUNITY - TBI
           54%                                                    ~69M                                                  $2.9B                                                      2:1                                         ~5.3M
     The increase of TBI-                                                                                                 Value of the global                             Male to female ratio.                                 The CDC's National
                                                                Individuals worldwide
      related emergency                                                                                                 traumatic brain injury                                                                                    Center for Injury
                                                               are estimated to sustain
    department visits from                                                                                                 assessment and                                                                                     Prevention and Control
                                                                   a TBI each year.
   2006-2014 in the United                                                                                              management devices                                                                                   estimates that 5.3 million
            States.                                                                                                        market in 2020.                                                                                   U.S. citizens (2 percent of
                                                                                                                                                                                                                             the population) are living
                                                                                                                                                                                                                             with disability as a result
TBI Sources: https://www.cdc.gov/traumaticbraininjury/get_the_facts.html
                                                                                                                                                                                                                                of a traumatic brain
https://thejns.org/view/journals/j-neurosurg/130/4/article-p1080.xml                                                                                                                                                                    injury.
https://www.grandviewresearch.com/industry-analysis/traumatic-brain-injuries-tbi-assessment-management-devices-market      PTSD Sources: https://www.therecoveryvillage.com/mental-health/ptsd/related/ptsd-statistics/#gref
https://www.ncbi.nlm.nih.gov/books/NBK459300/                                                                              https://www.reuters.com/article/us-health-mental-global/mental-health-crisis-could-cost-the-world-16-trillion-by-2030-idUSKCN1MJ2QN
https://www.cdc.gov/traumaticbraininjury/pdf/TBI_in_the_US.pdf                                                             https://www.psychiatrictimes.com/view/post-covid-stress-disorder-emerging-consequence-global-pandemic
CORPORATE PRESENTATION SEPTEMBER 2021 - Mziq
MTBI AND PTSD
The recommended concussion treatment from the Center of Disease Control:

  Discuss discharge instructions with patients and give them a discharge instruction sheet to
  take home and share with their family and/or caregiver. Be sure to:

       •   Alert patients to look for post concussive symptoms (physical, cognitive,
           emotional, and sleep) since onset of symptoms may not occur until days after the
           initial injury.
       •   Instruct patients on what to expect, what to watch for, and when it is important to
           return immediately to the emergency department.
       •   Emphasize that getting plenty of rest and sleep is very important after a
           concussion, as it helps the brain to heal. Patients should gradually return to their
           usual routine only after they start to feel better.

     There is no standard medicine recommended for treatment of mTBI.
             Recent studies have proven the efficacy of treating mTBI and
                                   PTSD with NAC
                                                                                     https://www.cdc.gov/traumaticbraininjury/pdf/TBI_Patient_Instructions-a.pdf
                                                                                     https://clinicaltrials.gov/ct2/show/NCT02499029
                                                                                     https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553161/
CORPORATE PRESENTATION SEPTEMBER 2021 - Mziq
PSYCHEDELICS AND NAC
                              Psychedelics Defined: Psychedelics (serotonergic hallucinogens)
                              are powerful psychoactive substances that alter perception and
                              mood and affect numerous cognitive processes. They are
                              generally considered physiologically safe and do not lead to
                              dependence or addiction.(1)

                                                                                          Some Common Psychedelic Drugs:
                                                                                          LSD –Lysergic Acid Diethylemide
                                                                                          DMT - Dimethyltryptamine
                                                                                          Psilocin/Psilocybin – Magic Mushrooms
                                                                                          MDMA (Ecstasy) - 3,4-methylenedioxy-methamphetamine
                                                                                          Mescaline/Peyote

               Psilocybin Mushrooms

           N-acetylcysteine (NAC) is a dietary supplement derived
           from the amino acid L-cysteine. It is used as an antidote for
           acetaminophen overdose. As an antioxidant, it is thought
           to reduce DNA damage. NAC is also marketed for its liver-
           protective properties and to support healthy immune
           functioning.(2)
                                                                                               NAC has been used in multiple studies to
                                                                                               treat mild Traumatic Brain Injuries. (mTBI)(3)
     1.   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813425/
     2.   https://www.mskcc.org/cancer-care/integrative-medicine/herbs/n-acetylcysteine
     3.   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3989181/
CORPORATE PRESENTATION SEPTEMBER 2021 - Mziq
SERATONIN RECEPTOR ACTIVATION

  The 5-HT2A is a G-protein-coupled receptor,
  commonly found in serotonin-rich areas of
  the brain, which is thought to manifest
  psychedelics’ effects (Kyzar et al. ,2017).

  Activation of this receptor results in the
  increased expression of key genes involved
  in creating new synapses in the brain.
  (Nichols & Sanders-Bush, 2002).

  This could influence the plasticity of neurons
  after a single dosage, establishing new long-
  term connections.

                                                   Figure adapted from Lowe et al., 2021
“RESET” BRAIN ACTIVITY PATTERNS

  Psychedelics may disrupt and rewire existing                PLACEBO                               PSILOCYBIN
  communication networks within the brain to
  create new, short-lived and persisting
  connectivity between brain regions, not
  normally associated.

  Neuroimaging psilocybin, ayahuasca, and
  LSD studies show decreases in older,
  established connections between brain
  areas, and increases new activity that
  correlates with positive subjective reports in
  brain function*.
                                                                 Figure adapted from Bullmore and Sporns, 2009

  One researcher calls this phenomenon as
  the brain’s “reset” button.(Carhart-Harris et
  al., 2017)                                       *Bullmore & Sporns, 2009; Carhart-Harris et al.,2012; Carhart-Harris et al., 2017
RESEARCH FOCUS                                    TBI

Research on psychedelics and Traumatic Brain
Injury (TBI) is limited.

There are investigations in rodent models that
describe the promising effects of psychedelics,
particularly MDMA on TBI.

Researchers found mild TBI preceded by one low
dose was neuroprotective. It prevented decreases
of key neuronal markers after injury, and the
treated mice showed cognitive improvements.
(Edut et al., 2011; Edut et al., 2014)

There are no noted studies or clinical trials related
to TBI and the classic psychedelics.

LOBE SCIENCES AND THE UNIVERSITY OF MIAMI
DATA ANALYSIS UPCOMING
                                                        Photo by Brainline
ANTI-INFLAMMATORY MECHANISMS

Research links pathological inflammation and chronic
diseases. (Zhong & Shi, 2019)

Psychedelics including LSD, have been shown to have
anti-inflammatory effects, by inhibiting a key
proinflammatory protein (TNF).

Additionally, psychedelics may reduce inflammation-
related gene expression (including IL-6) after receptor
activation.

Psychedelics may have a novel mechanism, reducing
inflammation through intracellular mechanisms instead
of reducing TNF from circulation.
UNIVERSITY OF MIAMI
                                               PRECLINICAL STUDIES
Early in 2021 The company launched preclinical research studies using psilocybin and N-
Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injury/concussion (“mTBI”) with
post-traumatic stress disorder (“PTSD”)

•   The study is in collaboration with a multidisciplinary team of scientists and physicians at the
    University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D.,
    professor of otolaryngology and neurological surgery.

•   NAC has been shown to be safe and efficacious in a phase I human clinical study in treating
    military personnel who had suffered mTBI.

•   The initial research focus is to demonstrate the safety and efficacy of the combination of
    psilocybin and NAC using broadly accepted rodent models.

•   The research team at the Miller School of Medicine has conducted prior studies involving NAC
    with mTBI and has a license from the United States Drug Enforcement Administration to
    conduct research using Schedule I controlled substances, which includes psilocybin.

•   Final results are expected in Q4 2021.
Preclinical Data: Light/Dark Box Experiment

A light dark emergence task is performed by placing rats
in a specially designed box/chamber that has a dark and
lighted side

Rats naturally seek the lighted side

Rats with stress or injury tend not be as aggressive at
seeking the lighted side
Light Dark Box Results

Rodents treated with the combination of psilocybin and NAC performed
statistically significantly better (P < 0.000005) than the rodents treated
with monotherapy with psilocybin, NAC or placebo.
INTELLECTUAL PROPERTY
            Microdosed
          Applications and               Medical Devices
            Compounds

              Lobe Sciences Patents Pending:
• Psilocybin combined with NAC for the   • Nasal Mist Transducer Device
  treatment of mTBI and PTSD and other     for delivery of medicines
  conditions                               directly to the Olfactory Bulb
• MDMA combined with NAC for the         • Virtual Reality Headset
  treatment of mTBI and PTSD and other     combined with the Nasal
  conditions                               Mist Device
• Addition of compounds to create
  memory odor imprint pairing
COLLABERATIONS
JOINT VENTURE
     WITH VPI

Development of Krysalis(TM) Therapeutic Pod to Deliver Headset-free Virtual Experience with
Biometric Monitoring with Virtual Psychedelics:

•   Partnered with industry-leading pioneers, including Hollywood director Brett Leonard and
    researcher and USC professor Dr. Skip Rizzo, with respect to the joint design, development
    and commercialization of a new psychedelic/virtual experience ("VX") pod.

      •   The Pod will be designed to be powered by a custom tech stack incorporating advanced
          display technology and state-of-the-art bio-monitoring with the goal of improving
          psychedelic therapy by optimizing set, setting and the overall experience for clinical and
          other uses.

•   The KrysalisTM Pod will be designed as a headset-free, virtual experience that uses multi-
    sensory stimulation to create an application that can offer treatment options for cognitive,
    psychological, motor and functional impairments across a wide range of clinical health
    conditions.
VITAMIND
                                                    AQUISITION
•   Addition of consumer packaged goods ("CPG") line of functional mushroom products further
    expands Lobe's operations and reach across the psychedelic space.

•   Vitamind is a brand of non-psychedelic functional mushroom products that includes three
    product lines which are specifically focused on boosting immune response and increasing
    mental clarity.

•   The Vitamind line of products are adaptogenic functional mushroom extract blends, which are
    specifically designed to promote wellness, including supporting immune response, and mental
    clarity, including improving memory function and reducing anxiety.

      •   Products include a blend of reishi, cordyceps, lion's mane, turkey tail, mesima, maitake,
          bacopa and/or shitake mushrooms.

      •   The products consist of multiple delivery forms, including capsules, tea bags and
          powder, allowing for ease of consumption and convenience, catering to consumer
          preferences.
•     The joint venture gives Lobe the potential to provide cGMP grade psilocybin for the use in
          clinical studies it plans to initiate in the future.

    •     Core One Labs will develop and manage the cGMP production and delivery of biosynthetic
          psilocybin.

• The device includes a nasal delivery system for administration of pharmaceutical agents such as
  a psilocybin-derived agent preselected dosages.
•       Successful completion of phase one development of the device.
          • A test platform was constructed and used to quantify key characteristics of the actuator, atomizer, and
             control system.
          • The testbed was also used to refine the mist volume, quality, and spray pattern.
          • The results reflect a clear path for delivering precise doses of drugs to the upper region of the nasal
             cavity.
COWLITZ DIVESTITURE
         On March 8, 2021 the company completed the sale of Washington-based Cowlitz County
         Cannabis Cultivation Inc. to Ionic Brands Corp.

         •   Strengthened Lobe's balance sheet with C$1.75 million cash on closing
         •   Lobe Sciences received 100,406,701 series E non-voting preferred shares of CNSX:IONC which
             convert on a one-to-one basis and carry an annual dividend of 13% for a period of two years

         •   Lobe Sciences also received 4,000,000 five year C$0.30 Ionic Brand warrants

IONIC BRANDS is a national cannabis
holdings company based in
Washington, led by a team of
successful entrepreneurs. The
company is focused on building a
multi-state consumer-focused
cannabis concentrate brand portfolio
focusing on the premium and luxury
segments.
ROADMAP & TIMELINES 2021 - 2022
                             2021                                                                                             2022

              Q2                      Q3                               Q4                             Q1                               Q2                       Q3

       UNIVERSITY OF MIAMI PRECLINICAL STUDY In TBI and PTSD
          Initiate Testing               Final Testing and Analysis          Data Report

                                           First In Man Study, Psilocybin & NAC
                                                CRO Selection and                Protocol Development and           Regulatory Review and Approval
                                                Feasibility Analysis                   Site Selection                   First Patient First Dose

                                    Identification of Manufacturing Partner To Support Trials and IND
                                     Evaluate Potential               Binding Agreement for cGMP                 Production of
                                         Partners                     Product and DMF                        Clinical Trial Material

                                              File Pre-IND and IND With FDA
                                                   Regulatory Analysis                     Pre IND Meeting                                  File IND
                                                       and Plan
Nasal Delivery Device Development
             Prototype Development                                              Implement Go To Market                                        Go To Market Design
                   and Testing                                                    Design and Feasibility                                           Selection
OUR TEAM
                        PHILIP                                                                                                                MAGHSOUD
                        J. YOUNG                                                    BRIAN                                                     DARIANI
                                                                                    ZASTIKO

CEO & Director                                               Chief Financial Officer                                     Chief Science Officer
Mr. Young has served as a Director and Chief Executive       Brian has over 13 years of experience across a variety      Prior to leading science and technology efforts at LOBE,
Officer for public companies for the past 20 years where     of private and public sector companies in the cannabis,     Dariani was President of Focus Pharmaceuticals, Inc.,
has had created significant shareholder value, built         agriculture, manufacturing, and utility industries. He      where he managed the development and approval of
integrated scientific, manufacturing and commercial          has extensive experience in financial reporting and         drug products, achieving one FDA approval and
operations, directed successful M&A transactions and was     corporate governance, as well as in the capital             bringing another to the clinical evaluation stage, then
responsible for generating more the $900M through            markets. Previously, Brian was a manager at Ernst &         successfully negotiated the sale of the company in
acquisitions and equity financings.                          Young LLP, where he obtained his CPA, CA designation.       February 2003.

                             JONATHAN                                                 LEIGHTON                                                   MICHAEL
                             GILBERT                                                  BOCKING                                                    PETTER

Executive Chairman                                           Director                                                    Director
Jonathan was the founder and CEO at Tassili LifeSciences,    Leighton has been working in the capital markets for over   Michael is an accomplished leader and entrepreneur in the
Corp., a biotech firm conducting research utilizing          15 years. His primary role has been as an independent       psychedelics and cannabis industry, co-founding and acting as a director
Psilocybin. Tassili was successfully acquired by a public    corporate development consultant in addition to holding     of several companies that successfully completed M&A transactions. He
company in March of 2020. He was also the founder and        various directorship positions. Leighton has been           holds a Bachelors in Computer Science from London University, is
CEO of Scythian Biosciences, Inc. from December of 2014      particularly focused on financing and structuring           a Chartered Engineer and private pilot. Since January 2009, he has been
through May of 2018. Prior to founding Scythian              companies. An active investor, he started in the industry   the Managing Director of Eyvo eProcurement Solutions, a US-based
Biosciences, from January 2013 to December 2014, Gilbert     at Canaccord before moving to the public company side       private company that is a leading eProcurement provider in the
was Marketing Officer for Commonwealth Opportunity           of the business.                                            SaaS space. Mike was co-founder and director of Eleusian Biosciences
Capital, GP, a hedge fund based in Greenwich, Connecticut.                                                               Corp., which the Company acquired in July 2020.
OUR TEAM

      DR. MARK A. GEYER PHD.                                                 CHARLES S. GROB MD.                                                 BENJAMIN KELMENDI MD.
  Scientific Advisor                                             Scientific Advisor                                                        Scientific Advisor
  Dr. Geyer is Distinguished Professor of Psychiatry and         Charles S. Grob, M.D. is Professor of Psychiatry and Pediatrics at the    Benjamin is a psychiatrist and an Associate Professor in the
  Neurosciences Emeritus at the University of California San     UCLA School of Medicine. He previously held faculty positions at the      Department of Psychiatry at the Yale University School of
  Diego (UCSD) and directs the Neuropsychopharmacology           Johns Hopkins School of Medicine and the University of California at      Medicine. His primary clinical expertise is in PTSD, Depression,
  Unit of the VISN 22 Veterans Administration Mental Illness     Irvine. From 2004-2008 he was the Principal Investigator of the first     OCD, and the endocannabinoid system. He is the co-founder of
  Research, Clinical, and Education Center. He has published     study in several decades to examine the use of a psilocybin treatment     the Yale Psychedelic Science Group. He leads a research
  over 470 peer-reviewed papers, including many addressing       model for patients with advanced-cancer anxiety. He has also              program focused on the therapeutic potential of psychedelic
  the mechanisms subserving the effects of                       conducted research into the range of effects of MDMA, in both normal      medicines, across a range of psychiatric diagnoses.
  psychostimulants, psychedelics, and entactogens.               volunteers and in a selected subject population of adult autistics with
                                                                 severe social anxiety.

                ILAN HAYMAN                                                          BART OATES                                                   GILBERTO JESÚS MENDOZA
Advisor                                                           Advisor
Ilan has played a pivotal role in the General Management of                                                                                Advisor
                                                                  Bart Oates Esq. is a three-time Superbowl Champion, who graduated        Gilberto Jesús Mendoza is currently the President of the World
healthcare businesses including a private cosmetic surgery        magna cum laude with a Juris Doctor degree from Seton Hall during
chain and the commercialization of a breakthrough skincare                                                                                 Boxing Association. Mr. Mendoza began his career as a lawyer
                                                                  his off season. Bart was selected to five Pro Bowls during his NFL       and an engineer and has been working with the WBA since
range. He successfully led the development of these products      career and to the UPI All-NFC team three times. Bart is now the
from concept through to production commercialization. Most                                                                                 2015. Mr. Mendoza is the proud creator of "Un Solo Boxeo"
                                                                  President of the NFL Alumni Association which offers former players a    (Only One Boxing), a program that promotes the integration of
recently Ilan oversaw a group of national medical centers. His    diverse package of medical, business, and legal services to help keep
career into operations management was triggered by his                                                                                     professional boxing. He also created the Future WBA
                                                                  them and their families healthy, productive, and connected to their      Champion, a project that has given space to thousands of
valuable experience as part of the Risk and Controls Solutions    former teammates.
practice at PricewaterhouseCoopers (PwC).                                                                                                  boxers in their preparation stage for the Tokyo Olympic Games.
FULLY DILUTED SHARE CAPITAL

                                                  Number                           Price           Expiry

      Issued & Outstanding                            219,133,984 (5/21/2021)

      Stock Options                                     15,693,836              $0.08 - $0.35   7/15/2021 – 5/30/2028

      Warrants                                          47,679,544              $0.20 - $0.75   5/15/2021 – 10/2/2023

      Performance Warrants                                 4,655,992                   $0.35          5/18/2026(1)

      Total Fully Diluted                              287,163,356

       Market Cap as of 08/30/2021: ~$23M CAD

       Public Equities trade on
                  CSE: LOBE
                  OTC Pink: GTSIF
       1   Subject to earlier expiry provisions
Thank You!!

         Contact:
         Philip Young, CEO
         phil@lobesciences.com
         (949) 505-2653
You can also read